Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hose

Showing results (71-80 of 189) with videos related to

Pageof 19
Sort By:
BMC Medical Genomics|December 31, 2015
Profound impact of sample processing delay on gene expression of multiple myeloma plasma cellsTobias Meißner, Anja Seckinger, Kari Hemminki, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 2, 2022
Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesisInge Oudaert, Hatice Satilmis, Philip Vlummens, et al.
Haematologica|November 22, 2011
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myelomaAlboukadel Kassambara, Dirk Hose, Jérôme Moreaux, et al.
Oncotarget|October 17, 2015
miRNAs in multiple myeloma--a survival relevant complex regulator of gene expressionAnja Seckinger, Tobias Meißner, Jérôme Moreaux, et al.
Oncotarget|February 12, 2015
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myelomaKen Maes, Eva De Smedt, Alboukadel Kassambara, et al.
Journal of Medical Economics|November 8, 2022
Systematic literature review of health economic models developed for multiple myeloma to support future analysesMimi Choon-Quinones, Tamás Zelei, Bertalan Németh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimensTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Leukemia|September 9, 2020
RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myelomaChunyan Gu, Ting Lu, Wang Wang, et al.
Oncoimmunology|July 29, 2016
Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitroIsabelle Krämer, Melanie Engelhardt, Sabrina Fichtner, et al.
Haematologica|October 17, 2009
Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myelomaJo Caers, Dirk Hose, Ine Kuipers, et al.
Pageof 19

Showing results (71-80 of 189) with videos related to

Sort By:
Pageof 19
BMC Medical Genomics|December 31, 2015
Profound impact of sample processing delay on gene expression of multiple myeloma plasma cellsTobias Meißner, Anja Seckinger, Kari Hemminki, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 2, 2022
Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesisInge Oudaert, Hatice Satilmis, Philip Vlummens, et al.
Haematologica|November 22, 2011
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myelomaAlboukadel Kassambara, Dirk Hose, Jérôme Moreaux, et al.
Oncotarget|October 17, 2015
miRNAs in multiple myeloma--a survival relevant complex regulator of gene expressionAnja Seckinger, Tobias Meißner, Jérôme Moreaux, et al.
Oncotarget|February 12, 2015
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myelomaKen Maes, Eva De Smedt, Alboukadel Kassambara, et al.
Journal of Medical Economics|November 8, 2022
Systematic literature review of health economic models developed for multiple myeloma to support future analysesMimi Choon-Quinones, Tamás Zelei, Bertalan Németh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2015
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimensTilmann Bochtler, Ute Hegenbart, Christina Kunz, et al.
Leukemia|September 9, 2020
RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myelomaChunyan Gu, Ting Lu, Wang Wang, et al.
Oncoimmunology|July 29, 2016
Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitroIsabelle Krämer, Melanie Engelhardt, Sabrina Fichtner, et al.
Haematologica|October 17, 2009
Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myelomaJo Caers, Dirk Hose, Ine Kuipers, et al.
Pageof 19